Y-mAbs Therapeutics, Inc. Prices 6M Share IPO at $16/Sh

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $96 million, before underwriting discounts and commissions and estimated offering expenses payable by the Company. All shares are being offered by the Company.

In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock from the Company at the initial public offering price, less underwriting discounts and commissions.

The Company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “YMAB” on Friday, September 21, 2018. The offering is expected to close on Tuesday, September 25, 2018, subject to customary closing conditions.

BofA Merrill Lynch and Cowen are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering and BTIG is acting as co-manager for the offering.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
• MEXC Partners with Kaito on $200K Stock Education Campaign During MEXC 0808 Stock Season